AbbVie has been a surprisingly strong performer of late. Can the stock keep it up?…
AbbVie has been a surprisingly strong performer of late. Can the stock keep it up?…
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock…
AbbVie (ABBV) issues the second CRL for Parkinsons disease medicine, ABBV-951, based on some observations on inspection of one of…
The Global Contraceptive Drugs Market Size was Valued at USD 18.53 Billion in 2023 and the Worldwide Contraceptive Drugs Market…
The Global Parkinsons Disease Treatment Market Size was Valued at USD 4.91 Billion in 2023 and the Worldwide Parkinsons Disease…
AbbVie sets quarterly dividend at $1.55 per share…
…
FDA approves Mercks (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVies (ABBV) Skyrizi and AstraZenecas (AZN)…
Wien (www.aktiencheck.de) - AbbVie-Aktienanalyse von der Raiffeisen Bank International AG:
Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt die…
Alzheimer’s disease treatment stocks are focused on Alzheimer’s disease, a degenerative brain disorder that results in declining memory and thinking…
AbbVies (ABBV) Skyrizi is now approved for four indications across immune-mediated inflammatory diseases.…
…
Minneapolis (www.aktiencheck.de) - AbbVie-Aktienanalyse von Piper Sandler:
Piper Sandler erhöht in einer aktuellen Aktienanalyse das Kursziel für die Aktie von AbbVie…
The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size…
The Global Prostate Health Market Size was Valued at USD 32.6 Billion in 2023 and the Worldwide Prostate Health Market…
NEW YORK, June 08, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating…
AbbVies tight grip on Humira market raises concerns about biosimilars…
Data from a mid-stage study shows that treatment with AbbVies (ABBV) Elahere achieves an objective response rate of almost 52%…
Eli Lillys (LLY) CFO Anat Ashkenazi resigns. CHMP recommends the expanded use of AbbVies (ABBV) Skyrizi and AstraZenecas (AZN) Tagrisso.…
The late-stage study will evaluate AbbVies (ABBV) experimental antibody to treat patients with relapsed/refractory multiple myeloma who have received at…
Heute vor 1 Jahr wurden AbbVie-Anteile wochenend-bedingt nicht via Börse NYSE gehandelt. Der Schlusskurs der AbbVie-Aktie betrug am vorangegangen…
AbbVie (ABBV) announces that the EMAs CHMP issued a positive opinion on its regulatory filing seeking label expansion for the…
NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating…
The Global Dyspepsia Drugs Market Size was Valued at USD 9.5 Billion in 2023 and the Worldwide Dyspepsia Drugs Market…
…
Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.…
AbbVies returns havent been great this year, but investors shouldnt overlook this promising growth stock.…
NEW YORK, May 25, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating…
Basel - Der Basler Accelerator und Inkubator BaseLaunch, der neue Biotechfirmen in ihrer Frühphase finanziert und unterstützt, hat den US-Pharmakonzern…
NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Bleichmar Fonti & Auld LLP is investigating the merger between…
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…
Im Plus liegt zur Stunde die AbbVie-Aktie . Zuletzt zahlten Investoren für die Aktie 166,22 US-Dollar. Freuen können sich gegenwärtig…
Dublin, May 17, 2024 (GLOBE NEWSWIRE) -- The "Non Hodgkin Lymphoma (NHL) Global Market Report 2024" report has…
Fake studies have flooded publishers of top scientific journals,. leading to thousands of retractions and millions of dollars in lost…
AbbVie (ABBV) inks an option-to-license and collaboration deal with Gilgamesh to develop next-generation therapies for psychiatric disorders.…
Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE) and AbbVie (ABBV) announce their first-quarter results.…
AbbVie has two successors that could offset the losses from its blockbuster drug Humira. Meanwhile, UnitedHealth Groups CEO will testify…
AbbVie Deutschland GmbH & Co. KG: Ludwigshafen (ots) - - Modernste Rahmenbedingungen für Forscher*innen im Kampf gegen u.a. Alzheimer und…
Wien (www.aktiencheck.de) - AbbVie-Aktienanalyse von der Raiffeisen Bank International AG:
Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt die…
ABBV earnings call for the period ending March 31, 2024.…
…
Jim Cramer offers his take on companies outside the CNBC Investing Club’s portfolio.…
Skyrizi brought in $2.01 billion in sales, just barely trailing the $2.27 billion generated by the struggling Humira.…
…
AbbVie raises annual profit forecast on strong Skyrizi sales…
AbbVie hikes 2024 earnings guidance as Q1 beat estimates, shares up…
AbbVie earnings beat by $0.04, revenue topped estimates…
…
Dublin, April 24, 2024 (GLOBE NEWSWIRE) -- The "Weight Loss Drugs Global Market Report 2024" report has been…